Elina Fredlund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elina Fredlund has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Elien Hilgert
Department of Biomolecular Medicine, Faculty of Medicine & Health Sciences, Ghent University; Cancer Research Institute Ghent (CRIG), Ghent, Belgium
1 shared publication Emma Magnusson
Division of Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden
1 shared publication- Emma U. Hammarlund
Department of Experimental Medical Science, Lund University, Lund, Sweden
1 shared publication Enrika Miltenyte
Division of Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden
1 shared publicationEstelle Lecomte
Division of Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden
1 shared publicationEzequiel Monferrer
Department of Pathology, Medical School, University of Valencia-INCLIVA Biomedical Health Research Institute, Valencia, Spain
1 shared publication
Latest Publications
- Open Access
- 21 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (25) , eado1583
MOXD1 is a lineage-specific gene and a tumor suppressor in neuroblastoma
Neuroblastoma is a childhood developmental cancer; however, its embryonic origins remain poorly understood. Moreover, in-depth studies of early tumor-driving events are limited because of the lack of appropriate models. Herein, we analyzed RNA sequencing data obtained from human neuroblastoma samples and found that loss of expression of trunk neural crest–enriched gene MOXD1 associates with advanced disease and worse outcome. Further, by using single-cell RNA sequencing data of human neuroblastoma cells and fetal adrenal glands and creating in vivo models of zebrafish, chick, and mouse, we show that MOXD1 is a determinate of tumor development. In addition, we found that MOXD1 expression is highly conserved and restricted to mesenchymal neuroblastoma cells and Schwann cell precursors during healthy development. Our findings identify MOXD1 as a lineage-restricted tumor-suppressor gene in neuroblastoma, potentiating further stratification of these tumors and development of novel therapeutic interventions.
- 21 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (25) , eado1583
Open AccessMOXD1 is a lineage-specific gene and a tumor suppressor in neuroblastoma
Neuroblastoma is a childhood developmental cancer; however, its embryonic origins remain poorly understood. Moreover, in-depth studies of early tumor-driving events are limited because of the lack of appropriate models. Herein, we analyzed RNA sequencing data obtained from human neuroblastoma samples and found that loss of expression of trunk neural crest–enriched gene MOXD1 associates with advanced disease and worse outcome. Further, by using single-cell RNA sequencing data of human neuroblastoma cells and fetal adrenal glands and creating in vivo models of zebrafish, chick, and mouse, we show that MOXD1 is a determinate of tumor development. In addition, we found that MOXD1 expression is highly conserved and restricted to mesenchymal neuroblastoma cells and Schwann cell precursors during healthy development. Our findings identify MOXD1 as a lineage-restricted tumor-suppressor gene in neuroblastoma, potentiating further stratification of these tumors and development of novel therapeutic interventions.